1404531-05-0

Basic information

• Product Name: 2-amino-5-(4-butyryl-5-methylpyrazol-1-yl)benzamide
• Synonyms: 2-amino-5-(4-butyryl-5-methylpyrazol-1-yl)benzamide
• CAS NO: 1404531-05-0
• Molecular Weight: 286.334
• Mol File: 1404531-05-0.mol

Chemical Properties

• CAS DataBase Reference: 2-amino-5-(4-butyryl-5-methylpyrazol-1-yl)benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-amino-5-(4-butyryl-5-methylpyrazol-1-yl)benzamide(1404531-05-0)
• EPA Substance Registry System: 2-amino-5-(4-butyryl-5-methylpyrazol-1-yl)benzamide(1404531-05-0)

Safety Data

• Hazardous Substances Data: 1404531-05-0(Hazardous Substances Data)

Usage

General Description

2-amino-5-(4-butyryl-5-methylpyrazol-1-yl)benzamide is a chemical compound with the molecular formula C17H20N4O2. It is a derivative of benzamide and is a member of the pyrazole class of compounds. This chemical has potential applications in pharmaceutical research, particularly in the development of new drugs. It may be used as a building block in the synthesis of other compounds, or it may have specific biological activities that make it useful in drug design. Further research and testing are necessary to fully understand the properties and potential uses of 2-amino-5-(4-butyryl-5-methylpyrazol-1-yl)benzamide.

Upstream product

• 1404530-78-4 1-[1-(4-aminophenyl)-5-methyl-1H-pyrazol-4-yl]butan-1-one 
• 1404530-79-5 ethyl 3-[5-methyl-1-(4-nitrophenyl)-1H-pyrazol-4-yl]-3-oxopropanoate 
• 1404530-82-0 ethyl 2-{[5-methyl-1-(4-nitrophenyl)-1H-pyrazol-4-yl]carbonyl}butanoate 
• 1404530-84-2 1-[5-methyl-1-(4-nitrophenyl)-1H-pyrazol-4-yl]butan-1-one 
• 1279832-24-4 1-[1-(4-amino-3-bromophenyl)-5-methyl-1H-pyrazol-4-yl]butan-1-one 
• 1404530-98-8 2-amino-5-(4-butyryl-5-methyl-pyrazol-1-yl)benzonitrile 
• 350-46-9 4-Fluoronitrobenzene 
• 260973-82-8 5-methyl-1-(4-nitrophenyl)-1H-pyrazole-4-carboxylic acid ethyl ester 
• 134653-70-6 ethyl 2-[(dimethylamino)methylene]-3-oxobutanoate 
• 1404530-54-6 1-(5-methyl-1H-pyrazol-4-yl)butan-1-one 

Downstream Products

• 1404532-77-9 {3-[4-(4-butyryl-5-methyl-pyrazol-1-yl)-2-carbamoylphenylcarbamoyl]-5-chloro-indol-1-yl}acetic acid methyl ester 

Relevant articles and documents

N -[6-(4-Butanoyl-5-methyl-1 H -pyrazol-1-yl)pyridazin-3-yl]-5-chloro-1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1 H -indole-3-carboxamide (SAR216471), a Novel Intravenous and Oral, Reversible, and Directly Acting P2Y12 Antagonist

In the search of a potential backup for clopidogrel, we have initiated a HTS campaign designed to identify novel reversible P2Y12 antagonists. Starting from a hit with low micromolar binding activity, we report here the main steps of the optimization process leading to the identification of the preclinical candidate SAR216471. It is a potent, highly selective, and reversible P2Y12 receptor antagonist and by far the most potent inhibitor of ADP-induced platelet aggregation among the P2Y12 antagonists described in the literature. SAR216471 displays potent in vivo antiplatelet and antithrombotic activities and has the potential to differentiate from other antiplatelet agents.

DERIVATIVES OF N-[(1H-PYRAZOL-1-YL)ARYL]-1H-INDOLE OR 1H-INDAZOLE-3-CARBOXAMIDE, PREPARATION THEREOF AND APPLICATIONS THEREOF IN THERAPEUTICS

The present invention relates to compounds corresponding to formula (I): in which: A represents a divalent aromatic radical; X represents a —CH— group or a nitrogen atom; R1 represents a (C1-C4)alkyl or a (C1-C4)alkoxy; R2 represents a group Alk; R3 represents a hydroxyl or a group —NR7R8; R4 represents a hydrogen atom, a halogen atom, a cyano, a phenyl, a group Alk, a group OAlk or a group —NR9R10; R5 represents a hydrogen atom, a halogen atom or a group Alk; R6 represents a hydrogen atom, a halogen atom, a cyano, a group —COOAlk or a —CONH2 group.

DERIVATIVES OF N- [(1H-PYRAZOL-1-YL) ARYL] - 1H - INDOLE OR 1H - INDAZOLE - 3 - CARBOXAMIDE, THEIR PREPARATION AND THEIR USE AS P2Y12 ANTAGONISTS

The present invention relates to compounds corresponding to formula (I) and their use as P2Y12 antagonists for the treatment of cardiovascular diseases.